Otsuka and Ionis experimental ALS drug meets late-stage goal
Otsuka Pharmaceutical and Ionis Pharmaceuticals said their experimental drug met the main goal in a late-stage study in patients with a rare inherited form of amyotrophic lateral sclerosis.
Otsuka Pharmaceutical and Ionis Pharmaceuticals said on Tuesday that their experimental drug met the main goal of a late-stage study in patients with a rare inherited form of amyotrophic lateral sclerosis, or ALS.